Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Adding pertuzumab to trastuzumab-AI improves PFS in HER2-positive advanced breast cancer

Jackey Suen
08 Oct 2018

Adding pertuzumab to trastuzumab plus an aromatase inhibitor (AI) improves progression-free survival (PFS) in patients with HER2-positive metastatic or locally advanced breast cancer, the phase II PERTAIN study has shown.

“PERTAIN is the first randomized phase II trial to investigate pertuzumab plus trastuzumab and an AI in this patient setting,” wrote investigators of the study. “Preclinical models have suggested that HER2 blockade with pertuzumab and trastuzumab may inhibit HER2-oestrogen receptor crosstalk more efficiently, enhancing the antitumour activity of tamoxifen or oestrogen deprivation. Our study builds on these findings and those of the recently reported phase III ALTERNATIVE trial of lapatinib plus trastuzumab and an AI vs trastuzumab plus an AI alone.” [J Clin Oncol 2018;36:2826-2835]

In the open-label study, 258 patients with HER2-positive, hormone receptor-positive metastatic or locally advanced breast cancer were randomized to receive trastuzumab (8 mg/kg followed by 6 mg/kg every 3 weeks) plus an AI (oral anastrozole 1 mg every day or letrozole 2.5 mg every day) with or without pertuzumab (840 mg loading dose followed by 420 mg every 3 weeks). Among these patients, 75 in the pertuzumab plus trastuzumab arm and 71 in the trastuzumab arm also received induction chemotherapy.

PFS, the primary endpoint of the study, was significantly improved with pertuzumab plus trastuzumab and AI vs trastuzumab plus AI alone (stratified median, 18.89 months vs 15.8 months; stratified hazard ratio [HR], 0.65; 95 percent confidence interval [CI], 0.48 to 0.89; p=0.007). The PFS improvements with the addition of pertuzumab were observed across all predefined subgroups.

Among patients who did not receive induction chemotherapy, median PFS was 21.72 months in the pertuzumab plus trastuzumab arm vs 12.45 months in the trastuzumab arm (HR, 0.55; 95 percent CI, 0.34 to 0.88). Among those who received induction chemotherapy, median PFS was 16.89 months vs 16.85 months (HR, 0.75; 95 percent CI, 0.50 to 1.13).

The objective response rate (ORR) was numerically higher with the addition of pertuzumab to trastuzumab and AI (63.3 percent vs 55.7 percent with trastuzumab and AI alone; p=0.2537), mainly driven by complete responses (7.3 percent vs 0.9 percent).

Notably, median duration of response (DoR) in patients with confirmed complete/partial response was significantly longer in the pertuzumab plus trastuzumab arm vs the trastuzumab arm (27.1 months vs 15.11 months; HR, 0.57; 95 percent CI, 0.36 to 0.91; p=0.0181).

Grade ≥3 adverse events (AEs) were reported in 50.4 percent and 38.7 percent of the patients, respectively. The most common grade ≥3 AEs were hypertension (10.2 percent vs 11.3 percent), diarrhoea (7.1 percent vs 2.4 percent), neutropenia (3.1 percent vs 6.5 percent), and anaemia (3.9 percent vs 2.4 percent).

“The superior efficacy of pertuzumab plus trastuzumab and an AI was not associated with significantly improved ORR,” the investigators noted. “The significant PFS improvements with the addition of pertuzumab may have been driven by more sustained responses, as shown by the significant increase in DoR.”

“Identifying patients who are likely to gain the most benefit from the combination of endocrine therapy with pertuzumab and trastuzumab is important as, given our results, patients with HER2-positive and hormone receptor-positive disease may not always require a chemotherapy treatment that is associated with greater toxicity,” they suggested.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
29 Nov 2019
Metformin Extended Release 500 mg,750 mg, and 1000 mg
30 Nov 2018
New drug applications approved by US FDA as of 16 - 30 November 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US.